GLP-1 Agonists May Interfere with Cancer Imaging, Potentially Leading to Misdiagnosis

UK researchers have identified a concerning interaction between popular GLP-1 receptor agonist medications and cancer (search)Search disease imaging that could lead to misdiagnosis and unnecessary medical interventions. The findings, presented at the 38th Annual Congress of the European Association of Nuclear Medicine in Barcelona, reveal that drugs like OzempicView drug details, WegovyView drug details, MounjaroView drug details, and ZepboundView drug details can create unusual patterns in FDG PET-CT scans that may be mistaken for signs of disease.

Altered Imaging Patterns Raise Diagnostic Concerns

The research team from Alliance Medical Ltd (search)Search term conducted a retrospective case series review of FDG PET-CT scans in patients taking GLP-1 agonists. These combined imaging techniques use a radioactive form of glucoseView drug details to identify areas of high metabolic activity, such as tumors or inflammation, making them crucial tools for cancer (search)Search disease detection and monitoring.

"We noticed unusual uptake in one of our patients on a GLP-1 agonist, which prompted a wider review across our network," explained lead author Dr. Peter Strouhal, medical director at Alliance Medical Ltd (search)Search term. "We found that these altered patterns are increasingly common, yet there is currently no national or international guidance in the UK addressing this emerging issue."

The researchers observed atypical tracer uptake patterns that could be misinterpreted as disease if a patient's medication history is not properly considered during scan interpretation. Previous case reports have documented increased FDG uptake in skeletal muscle, heart muscle, and brown adipose tissue in patients taking these medications.

Clinical Implications and Patient Impact

The potential for misinterpretation carries significant clinical consequences. Misunderstanding these altered scan results could lead to unnecessary investigations, inappropriate cancer (search)Search disease staging, and delays in treatment. Beyond the medical implications, such misdiagnoses can cause considerable stress and anxiety for patients who may believe they have cancer or other serious conditions.

"Recognizing the characteristic uptake associated with GLP-1 agonists helps avoid unnecessary anxiety and interventions, ensuring patients receive the right care, at the right time, without detours or doubt," Dr. Strouhal stated.

Expert Perspectives on Clinical Significance

Medical experts not involved in the study have offered varying perspectives on the findings' clinical importance. Dr. Sue Decotiis, a medical weight-loss doctor in New York City, noted that the results remain preliminary. "They just noticed an increase, but it didn't mention which organs or specific body parts," she told Fox News Digital. "It will be important to see more data from many more patients to understand exactly what they saw."

Dr. Adam Wolfberg, chief medical officer at Virta Health (search)Search term in Massachusetts, provided context for the mechanism behind these observations. "GLP-1s have many effects on the body, and one of them is altering the way glucoseView drug details is metabolized," he explained. "Since the tracer agent used in these PET scans contains glucose, uptake of the agent — a metabolic 'dye' of sorts — can be impacted."

However, Wolfberg emphasized that skilled radiologists and oncologists typically interpret scans within the broader clinical context. "PET scans are always interpreted in the context of the whole patient," he said. "A skilled oncologist or radiologist would always take into account a patient's medical history as well as the medications they are taking when reading this type of scan."

Current Recommendations and Future Directions

Despite these findings, researchers do not recommend that patients discontinue GLP-1 medications before undergoing FDG PET-CT scans. Instead, they emphasize the importance of proper documentation and consideration of medication history during scan interpretation.

Nuclear medicine consultant physicist Heather Williams from The Christie, who was not involved in the study, noted that current best practices already call for comprehensive medical histories before scanning. "It is also usual practice for a medical history to be taken prior to the scan, which will include any other factors that may affect how the injection is taken up in different parts of the body — this includes all current medications and recent treatments," she explained.

The research team plans to extend their investigation across more imaging centers globally to provide evidence for more specific guidelines. They aim to collaborate internationally to develop formal guidance that will benefit patients worldwide who are taking these increasingly popular medications.

Growing Need for Updated Guidelines

The findings highlight a gap in current imaging protocols as GLP-1 agonist use continues to expand. While Australian guidance already references GLP-1 use and suggests continuing treatment with specific preparation protocols, no similar guidance exists in the UK or other regions.

The researchers stress that imaging teams should carefully document patients' medication histories and consider GLP-1 use when interpreting scan results while formal guidance is being developed. This approach could help prevent the cascade of unnecessary procedures and patient anxiety that may result from misinterpreted scans.

As the use of GLP-1 agonists continues to grow for both diabetes (search)Search disease management and weight loss, establishing clear imaging guidelines becomes increasingly critical for maintaining diagnostic accuracy and patient care quality.